REGENERON PHARMACEUTICALS INCBusiness Directories,Company Directories

Company Name: Corporate Name:	REGENERON PHARMACEUTICALS INC
Company Title:
Company Description:
Keywords to Search:
Company Address:	777 Old Saw Mill River Rd,TARRYTOWN,NY,USA
ZIP Code: Postal Code:	10591-6707
Telephone Number:
Fax Number:	9143457400 (+1-914-345-7400)
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	873108
USA SIC Description:	Pharmaceutical Research Laboratories
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
HUDSON CASTLE GROUP
TAC
DONALD GOODWIN

Next company profile:
PLCSI
INTERNATIONAL SPECIALTY CHMCLS
ALLIANCE ELECTRONICS INC.

Company News:

Regeneron | Pushing the Bounds of Science
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines Join our team and explore clinical trials
Regeneron Pharmaceuticals - Wikipedia
On February 4, 2020, the U S Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19
PUSH THE BOUNDS OF SCIENCE - Regeneron
Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases
Regenerons experimental therapy combo effective in untreated cancer . . .
Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the
About Regeneron | Our Company
We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® (RGC) and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases
ASH: Regeneron eyes simpler regimens in bid to move bispecifics into . . .
In essence, Regeneron is trying to move Lynozyfic and odronextamab into earlier lines of treatment by testing less onerous regimens than its rivals in the space
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin Moreover, as of September 30, Regeneron had about $2 2 billion remaining under its authorized share
Regeneron inks gene editing deal with startup Tessera
Regeneron Pharmaceuticals is putting more money into gene editing, announcing Monday a partnership with Tessera Therapeutics to develop an experimental program for a rare liver and lung disease At the center of the deal is a treatment Tessera, a well-funded startup backed by Flagship Pioneering, is developing for alpha-1 antitrypsin deficiency Regeneron is paying Tessera $150 million upfront
Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic . . .
Quiver AI Summary Regeneron Pharmaceuticals announced promising interim results from its Phase 1 2 LINKER-MM4 trial, which evaluated the efficacy of its bispecific antibody Lynozyfic™ (linvoseltamab) in adults with newly diagnosed multiple myeloma Data presented at the ASH Annual Meeting showed that all dose groups (50 mg, 100 mg, and 200 mg) achieved a very good partial response or better
Regeneron Pipeline Medicines in Development
Explore Regeneron’s pipeline of investigational medicines advancing through clinical trials for a range of serious diseases